Cosmo Pharmaceuticals N.V (C43) — Free Cash Flow Generation Index

Latest as of June 2022: 1.18x

Cosmo Pharmaceuticals N.V (C43) has a Free Cash Flow Generation Index of 1.18x as of June 2022. Free cash flow of €7.39 Million represents 1% of operating cash flow (€6.28 Million). Explore Cosmo Pharmaceuticals N.V capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.

FCF Generation Index

1.18x
Free Cash Flow / Operating CF

Free Cash Flow

€7.39 Million
EUR

Operating Cash Flow

€6.28 Million
EUR

Capital Expenditures

€1.11 Million
EUR

Cosmo Pharmaceuticals N.V Free Cash Flow Generation Index (2016–2024)

Historical FCF Generation Index trend for Cosmo Pharmaceuticals N.V across 6 annual periods. For the full cash flow conversion analysis, see C43 cash flow conversion.

Annual Free Cash Flow Generation for Cosmo Pharmaceuticals N.V (2016–2024)

Year-by-year Free Cash Flow Generation Index for Cosmo Pharmaceuticals N.V. Check C43 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Year FCG Index Free Cash Flow (EUR) Operating CF Capital Expenditures YoY Change
2024 0.97x €156.76 Million €162.41 Million €5.65 Million ▲ +77.2%
2023 0.54x €18.31 Million €33.62 Million €15.31 Million ▼ -30.2%
2022 0.78x €25.92 Million €33.23 Million €7.31 Million ▲ +139.5%
2021 0.33x €4.11 Million €12.61 Million €5.49 Million ▼ -13.7%
2020 0.38x €4.90 Million €12.98 Million €4.12 Million ▼ -79.6%
2016 1.85x €40.12 Million €21.69 Million €18.43 Million
FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).